You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
美FDA正式批准延緩阿茲海默症新藥
阿思達克 07-07 22:37
美國食品及藥物管理局(FDA)正式批准可延緩腦退化病阿茲海默症的新藥「Leqembi」,為20年來首款獲批的阿茲海默症新藥。 該藥由日本衛材(Eisai)及美國百健(Biogen)(BIIB.US)共同研發,臨床顯示對症狀較輕的早期阿茲海默症患者,可於十八個月內延緩病情惡化五個月,注射該新藥的病人,相較注射安慰劑的病人,認知能力下降速度減慢27%。 獲FDA正式批准,意味藥物可被納入政府醫保,患者只需負擔兩成費用。該款新藥每年費用為2.65萬美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account